In this observational cohort study we will be collecting bioelectrical impedance body composition data from women receiving routine chemotherapy before or after breast surgery. We will collect information for each patient about the chemotherapy drugs and doses they receive and the side effects they experience to investigate how different patterns of body composition affect response to chemotherapy.


  • To determine if Fat Mass index at baseline by bioelectrical impedance, as measured by mean Fat Mass corrected for differences in height, according to patients with/without grade ≥3 toxicity.
  • To determine the prognostic potential of bioelectrical impedance analysis-derived body composition measures including Fat Free Mass index in predicting grade 3 or higher chemotherapy toxicity.

Inclusion criteria

We plan to recruit those with early invasive breast cancer planned to receive greater than 4 x 21 day cycles of anthracycline or taxane based combination neo-adjuvant or adjuvant systemic chemotherapy. Those planned to receive the anthracycline component of the chemotherapy regimen at 2-weekly intervals (accelerated regimens) are also eligible.

Sample size

Three hundred participants (40-45 participants/site).


University Hospital Southampton NHS Foundation Trust; Royal Devon and Exeter NHS Foundation Trust; Salisbury NHS Foundation Trust; The Christie NHS Foundation Trust (Manchester); Oxford University Hospitals NHS Foundation Trust; Portsmouth Hospitals NHS Trust; Royal Cornwall Hospitals NHS Trust (Truro); and Leeds Teaching Hospitals NHS Trust.


An 18 month recruitment period with assessments prior to every chemotherapy cycle, 3 weeks after and then again at 3 months after their final chemotherapy cycle. The CANDO-3 study will be open to recruitment until 31st May 2024.


Contact information

Further information can be obtained by contacting